Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
GLP-1R activation of neuroprotective pathways in neurons, microglia and astrocytes has also been reported: improvements in overall cognition, learning and motor function potentially associated with GLP-1RA administration in Alzheimers disease and Parkinsons disease may be mediated not only by their amyloid pathology-ameliorating properties (A, tau and -synuclein), but also the suppression of Ca 2+ deregulation and endoplasmic reticulum stress, anti-inflammatory activity, blockage of oxidative stress, mitochondrial dysfunction and apoptosis pathways, enhancements in the neuronal insulin sensitivity and energy metabolism, functional improvements in autophagy and mitophagy, elevated brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis, and neurogenesis 36
To gain further insight into the mechanism of degradation we used mass spectrometry to analyse the pGLP-1 and eGLP-1 cleavage products
Tirzepatide (highest doses in SURMOUNT-1) produced average losses near or above 20%, depending on dose, with clear dose-response effects in pivotal trials
Presented at the 2025 Society of Hematologic Oncology Annual Meeting
Some research peptide vendors provide third-party certificates of analysis (COA) showing purity testing
Diabetes Obes Metab (2022) 24(2):28995
US$ 26.04
US$ 20.11
US$ 25.26
US$ 27.43
US$ 25.50
